enGene Holdings is trading at $1.73, up 10.90% in pre-market, with no clear company-specific or market catalyst identified.
- No October 26 company-specific announcement or clear overnight catalyst was identified; enGene’s latest listed press release is dated October 13.
- Recent updates discussed clinical development and anticipated pivotal data later in 2026, but did not establish a direct reason for the move.
- Provided index gains were modest, and available evidence does not clearly connect broader market sentiment to enGene’s rise.